Creative Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

Creative Planning’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$249K	Sell	67,955 -26,253	-28%	-$87.4K	﹤0.01%	3717
2026 Q1	$289K	Buy	94,208 +44,673	+90%	+$173K	﹤0.01%	3456
2025 Q4	$203K	Buy	49,535 +22,217	+81%	+$110K	﹤0.01%	3543
2025 Q3	$133K	Sell	27,318 -8,902	-25%	-$46.8K	﹤0.01%	3618
2025 Q2	$183K	Sell	36,220 -1,869	-5%	-$9.18K	﹤0.01%	3255
2025 Q1	$201K	Buy	38,089 +1,661	+5%	+$12.1K	﹤0.01%	3068
2024 Q4	$246K	Buy	+36,428	New	+$245K	﹤0.01%	2824
2023 Q4	–	Sell	-18,287	Closed	-$140K	–	3041
2023 Q3	$140K	Buy	+18,287	New	+$182K	﹤0.01%	2333

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Creative Planning's RXRX Position: Q2 2026 in Review

Creative Planning reduced its Recursion Pharmaceuticals (RXRX) stake by 28% in Q2 2026, selling an estimated $87.4K and leaving 67,955 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Creative Planning first reported a position in RXRX in Q3 2023 and has held it in 8 quarters since. The position peaked at $289K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Creative Planning held 67,955 shares of Recursion Pharmaceuticals worth $249K as of Q2 2026.
Creative Planning sold 26,253 Recursion Pharmaceuticals shares in Q2 2026, an estimated $87.4K.
Recursion Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3717 holding.
Creative Planning first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Creative Planning's Recursion Pharmaceuticals position peaked at $289K in Q1 2026.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.